Merck & Co., Inc. Income (Loss) from Continuing Operations, Per Diluted Share
Merck & Co., Inc. (MRK) reported Income (Loss) from Continuing Operations, Per Diluted Share of $0.14 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2024-02-26
- Merck & Co., Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2022-09-30 was $1.28, a 28.89% decline year-over-year.
- Merck & Co., Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2022-06-30 was $1.55, a 222.92% increase year-over-year.
- Merck & Co., Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2022-03-31 was $1.70, a 57.41% increase year-over-year.
- Merck & Co., Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2021-09-30 was $1.80, a 95.65% increase year-over-year.
- Merck & Co., Inc. income (loss) from continuing operations, per diluted share for fiscal 2023 was $0.14, a 97.55% decline from fiscal 2022.
- Merck & Co., Inc. income (loss) from continuing operations, per diluted share for fiscal 2022 was $5.71, a 17.49% increase from fiscal 2021.
- Merck & Co., Inc. income (loss) from continuing operations, per diluted share for fiscal 2021 was $4.86, a 173.03% increase from fiscal 2020.
- Merck & Co., Inc. income (loss) from continuing operations, per diluted share for fiscal 2020 was $1.78, a 19.46% decline from fiscal 2019.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.14 10-K · filed 2024-02-26 | |||
| 2022-12-31 | $5.71 10-K · filed 2024-02-26 | |||
| 2022-09-30 | $1.28 10-Q · filed 2022-11-03 | $4.53 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | $1.55 10-Q · filed 2022-08-05 | $3.25 10-Q · filed 2022-08-05 | ||
| 2022-03-31 | $1.70 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $4.86 10-K · filed 2024-02-26 | |||
| 2021-09-30 | $1.80 10-Q · filed 2022-11-03 | $3.36 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.48 10-Q · filed 2022-08-05 | $1.56 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | $1.08 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $1.78 10-K · filed 2023-02-24 | |||
| 2020-09-30 | $0.92 10-Q · filed 2021-11-05 | $2.81 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $0.92 10-Q · filed 2021-08-09 | $1.89 10-Q · filed 2021-08-09 | ||
| 2019-12-31 | $2.21 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |